References
- Adams G.E., Ahmed I., Sheldon P.W., Stratford I.J. Radiation sensitization and chemopotentiation: RSU-1069, a compound more efficient than misonidazole in vitro and in vivo. British Journal of Cancer 1984; 49: 571–578
- Chaplin D.J., Acker B. The effect of hydralazine on the tumour cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. International Journal of Radiation Oncology, Biology and Physics 1987; 13: 579–586
- Chaplin D.J., Durand R.E., Stratford I.J., Jenkins T.C. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumour. International Journal of Radiation Oncology, Biology and Physics 1986; 12: 1091–1095
- Cole, S., Robbins, L. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069. Radiotherapy and Oncology, In press, 1989
- Deacon J.M., Holliday S.B., Ahmed I., Jenkins T.C. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumour/plasma ratios. International Journal of Radiation Oncology, Biology and Physics 1986; 12: 1087–1090
- Dische S. Radiotherapy using the hypoxic cell sensitizer Ro-03-8799 in malignant melanoma. Radiotherapy and Oncology 1987; 10: 111–116
- Stratford I.J., Godden J., Howells N., Embling P., Adams G.E. Manipulation of tumour oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effects of melphalan in experimental tumours. Radiation Research, E.M. Fielden, J.F. Fowler, J.H. Hendry, D. Scott. Taylor & Francis, London 1987; 2: 737–742
- Stratford I.J., O'Neill P., Sheldon P.W., Silver A.R., Walling J.M., Adams G.E. RSU-1069, a nitroimidazole containing an aziridine group: bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochemical Pharmacology 1986a; 35: 105–109
- Stratford I.J., Walling J.M., Silver A.R.J. The differential cytotoxicity of RSU-1069: cell survival studies indicating interaction with DNA as a possible mode of action. British Journal of Cancer 1986b; 53: 339–344
- Walling J.M., Deacon J., Holliday S., Stratford I.J. High uptake of RSU-1069 and its analogues into melanotic melanomas: a cell-mediated event. Cancer Chemotherapy and Pharmacology 1989; 24: 28–32
- West C.M.L., Sandhu R.R., Stratford I.J. The radiation response of V79 and human tumour multi-cellular spheroids: cell survival and growth delay studies. British Journal of Cancer 1984; 50: 143–151
- Workman P., Walton M.I. Pharmacology of the mixed function radio- and chemosensitizers CB-1954 and RSU-1069. International Journal of Radiation Oncology, Biology and Physics 1984; 10: 1307–1311